Loading...
  • sirolimus
  • Therefore It will test the efficacy of combining sirolimus, tacrolimus, antithymocyte globulin, and rituximab in preventing graft versus host disease in transplants from HLA Haploidentical and partially mismatched donors. (clinicaltrials.gov)
  • graft
  • normal cells (called graft-versus-host disease). (aamds.org)
  • Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chromosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients with female donors (F→M). However, the temporal association between HY-Ab development and chronic graft-versus-host disease (cGVHD) has yet to be elucidated. (bloodjournal.org)
  • marrow
  • Defined by either morphological or cytogenetic evidence of chronic myelogenous leukemia (CML), AML, MDS or other myeloproliferative disease in marrow, blood, or other sites, or laboratory evidence of residual disease. (clinicaltrials.gov)
  • The treatment consists of medications that weaken the immune system so it doesn't reject the donor's marrow cells. (clinicaltrials.gov)
  • 5% blasts by morphology on a marrow aspirate or the presence of circulating blasts in the peripheral blood. (clinicaltrials.gov)